PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is
overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity …

Molecular profiling of circulating extracellular vesicles (EVs) provides a promising
noninvasive means to diagnose, monitor, and predict the course of metastatic breast cancer …

Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has
rapidly spread and is now regarded as a significant step forward in the diagnosis of …

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is
highly overexpressed on prostate cancer epithelial cells and for which there is a growing …

Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still
expanding. This group is very diverse in terms of peptide size. It contains very small …

Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …

Purpose 68 Ga ligands targeting prostate-specific membrane antigen (PSMA) are rapidly
emerging as a significant step forward in the management of prostate cancer. PSMA is a …

Simple Summary Positron emission tomography/computed tomography (PET/CT) has an
increasingly relevant role in the management of oncological patients. It consists of the …

The continuing adoption of prostate specific membrane antigen (PSMA)-targeted PET for
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …